Matrix control of pancreatic cancer: New insights into fibronectin signaling

Cancer Letters

Volumn 381, Issue 1, 2016, Pages 252-258

  Topalovski, Mary ^a   Brekken, Rolf A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Chemoresistance; Extracellular matrix; Fibronectin; Integrin; Metastasis; Pancreatic cancer

Indexed keywords

ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II; FIBRONECTIN; TENASCIN; VERY LATE ACTIVATION ANTIGEN 5; VOLOCIXIMAB; ANTINEOPLASTIC AGENT;

CANCER PROGNOSIS; CANCER RESISTANCE; CELL INVASION; CELL SURVIVAL; CIRCULATING TUMOR CELL; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; KIDNEY METASTASIS; MELANOMA; METASTASIS; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; STROMA; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; CARCINOMA, PANCREATIC DUCTAL; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; FIBROSIS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); PANCREATIC NEOPLASMS; PATHOLOGY; SECONDARY; TUMOR INVASION; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX; FIBRONECTINS; FIBROSIS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84954287786     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.12.027     Document Type: Review

References (119)

1. [1] Vincent, A., et al. Pancreatic cancer. Lancet 378:9791 (2011), 607–620.
2. [2] Smith, B.D., et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J. Clin. Oncol 27:17 (2009), 2758–2765.
3. [3] Lunardi, S., Muschel, R.J., Brunner, T.B., The stromal compartments in pancreatic cancer: are there any therapeutic targets?. Cancer Lett, 2014, 147–155.
4. [4] Erkan, M., et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol 6:10 (2008), 1155–1161.
5. [5] Sinn, M., et al. alpha-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Br. J. Cancer 111:10 (2014), 1917–1923.
6. [6] Alvarez, R., et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br. J. Cancer 111:8 (2014), 1677–1678.
7. [7] Lenselink, E.A., Role of fibronectin in normal wound healing. Int. Wound J. 12:3 (2015), 313–316.
8. [8] George, E.L., et al. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 119:4 (1993), 1079–1091.
9. [9] Pankov, R., Fibronectin at a glance. J. Cell Sci, 2002, 3861–3863.
10. [10] To, W.S., Midwood, K.S., Plasma and cellular fibronectin: distinct and independent functions during tissue repair. Fibrogenesis Tissue Repair, 4, 2011, 21.
11. [11] Midwood, K.S., Williams, L.V., Schwarzbauer, J.E., Tissue repair and the dynamics of the extracellular matrix. Int. J. Biochem. Cell Biol 36:6 (2004), 1031–1037.
12. [12] Ramaswamy, S., et al. A molecular signature of metastasis in primary solid tumors. Nat. Genet 33:1 (2003), 49–54.
13. [13] Ramakrishnan, V., et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J. Exp. Ther. Oncol 5:4 (2006), 273–286.
14. [14] Harburger, D.S., Calderwood, D.A., Integrin signalling at a glance. J. Cell Sci 122:Pt 2 (2009), 159–163.
15. [15] Kim, S., et al. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am. J. Pathol 156:4 (2000), 1345–1362.
16. [16] Lamalice, L., Le Boeuf, F., Huot, J., Endothelial cell migration during angiogenesis. Circ. Res 100:6 (2007), 782–794.
17. [17] Clark, R.A., et al. Blood vessel fibronectin increases in conjunction with endothelial cell proliferation and capillary ingrowth during wound healing. J. Invest. Dermatol 79:5 (1982), 269–276.
18. [18] de Fougerolles, A.R., et al. Regulation of inflammation by collagen-binding integrins alpha1beta1 and alpha2beta1 in models of hypersensitivity and arthritis. J. Clin. Invest 105:6 (2000), 721–729.
19. [19] Krieglstein, C.F., et al. Collagen-binding integrin alpha1beta1 regulates intestinal inflammation in experimental colitis. J. Clin. Invest 110:12 (2002), 1773–1782.
20. [20] Kim, S., et al. Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin. Am. J. Pathol, 2010, 1345–1362.
21. [21] Kim, C., Ye, F., Ginsberg, M.H., Regulation of integrin activation. Annu. Rev. Cell Dev. Biol, 2011, 321–345.
22. [22] Campbell, I.D., Humphries, M.J., Integrin structure, activation, and interactions. Cold Spring Harb. Perspect. Biol, 3(3), 2011.
23. [23] Calderwood, D.A., et al. The Talin head domain binds to integrin beta subunit cytoplasmic tails and regulates integrin activation. J. Biol. Chem 274:40 (1999), 28071–28074.
24. [24] Giancotti, F.G., Integrin Signaling. Science, 1999, 1028–1033.
25. [25] Vuori, K., Integrin signaling: tyrosine phosphorylation events in focal adhesions. J. Membr. Biol 165:3 (1998), 191–199.
26. [26] Lipfert, L., et al. Integrin-dependent phosphorylation and activation of the protein tyrosine kinase pp125FAK in platelets. J. Cell Biol 119:4 (1992), 905–912.
27. [27] Hsia, D.A., et al. Differential regulation of cell motility and invasion by FAK. J. Cell Biol 160:5 (2003), 753–767.
28. [28] Zhai, J., et al. Direct interaction of focal adhesion kinase with p190RhoGEF. J. Biol. Chem 278:27 (2003), 24865–24873.
29. [29] Lim, Y., et al. PyK2 and FAK connections to p190Rho guanine nucleotide exchange factor regulate RhoA activity, focal adhesion formation, and cell motility. J. Cell Biol 180:1 (2008), 187–203.
30. [30] Hildebrand, J.D., Taylor, J.M., Parsons, J.T., An SH3 domain-containing GTPase-activating protein for Rho and Cdc42 associates with focal adhesion kinase. Mol. Cell. Biol 16:6 (1996), 3169–3178.
31. [31] Zhao, X., Guan, J.L., Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv. Drug Deliv. Rev 63:8 (2011), 610–615.
32. [32] Webb, D.J., et al. FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat. Cell Biol 6:2 (2004), 154–161.
33. [33] Cary, L.A., Chang, J.F., Guan, J.L., Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn. J. Cell Sci 109:Pt 7 (1996), 1787–1794.
34. [34] Turner, C.E., Paxillin interactions. J. Cell Sci 113:Pt 23 (2000), 4139–4140.
35. [35] Eliceiri, B.P., Integrin and growth factor receptor crosstalk. Circ. Res 89:12 (2001), 1104–1110.
36. [36] Bouvard, D., et al. Integrin inactivators: balancing cellular functions in vitro and in vivo. Nat. Rev. Mol. Cell Biol, 2013, 430–442.
37. [37] Chang, D.D., et al. ICAP-1, a novel beta1 integrin cytoplasmic domain-associated protein, binds to a conserved and functionally important NPXY sequence motif of beta1 integrin. J. Cell Biol 138:5 (1997), 1149–1157.
38. [38] Rantala, J.K., et al. SHARPIN is an endogenous inhibitor of beta1-integrin activation. Nat. Cell Biol 13:11 (2011), 1315–1324.
39. [39] Aota, S., Nomizu, M., Yamada, K.M., The short amino acid sequence Pro-His-Ser-Arg-Asn in human fibronectin enhances cell-adhesive function. J. Biol. Chem 269:40 (1994), 24756–24761.
40. [40] Koay, E.J., et al. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J. Clin. Invest, 2014, 1525–1536.
41. [41] Schober, M., et al. Desmoplasia and chemoresistance in pancreatic cancer. Cancers, 2014, 2137–2154.
42. [42] Neesse, A., et al. Stromal biology and therapy in pancreatic cancer. Gut, 2011, 861–868.
43. [43] Yauch, R.L., et al. A paracrine requirement for hedgehog signalling in cancer. Nature, 2008, 406–410.
44. [44] Wong, K.S., et al. Hedgehog signaling is required for differentiation of endocardial progenitors in zebrafish. Dev. Biol 361:2 (2012), 377–391.
45. [45] Olive, K.P., et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science, 2009, 1457–1461.
46. [46] Chauhan, V.P., et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun, 4, 2013, 2516.
47. [47] Toole, B.P., Slomiany, M.G., Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin. Cancer Biol 18:4 (2008), 244–250.
48. [48] Campistol, J.M., et al. Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Kidney Int 56:2 (1999), 714–719.
49. [49] Habashi, J.P., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312:5770 (2006), 117–121.
50. [50] Provenzano, P.P., et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell, 2012, 418–429.
51. [51] Jacobetz, M.A., et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62:1 (2013), 112–120.
52. [52] Stromnes, I.M., et al. Stromal reengineering to treat pancreas cancer. Carcinogenesis 35:7 (2014), 1451–1460.
53. [53] Shi, Q., et al. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin. Cancer Res 5:11 (1999), 3711–3721.
54. [54] Miyamoto, H., et al. Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 28:1 (2004), 38–44.
55. [55] Han, S., Khuri, F.R., Roman, J., Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res 66:1 (2006), 315–323.
56. [56] Chen, H.C., Guan, J.L., Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase. Proc. Natl. Acad. Sci. U.S.A. 91:21 (1994), 10148–10152.
57. [57] Li, P., et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:4 (1997), 479–489.
58. [58] Czabotar, P.E., et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell Biol 15:1 (2014), 49–63.
59. [59] Schlaepfer, D.D., et al. Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature 372:6508 (1994), 786–791.
60. [60] Reuter, S., et al. Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic. Biol. Med, 2010, 1603–1616.
61. [61] Edderkaoui, M., et al. Extracellular matrix stimulates reactive oxygen species production and increases pancreatic cancer cell survival through 5-lipoxygenase and NADPH oxidase. Am. J. Physiol. Gastrointest. Liver Physiol 289:6 (2005), G1137–G1147.
62. [62] Hwang, R.F., et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 68:3 (2008), 918–926.
63. [63] Vonlaufen, A., et al. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res 68:7 (2008), 2085–2093.
64. [64] Neesse, A., et al. Pancreatic stellate cells potentiate proinvasive effects of SERPINE2 expression in pancreatic cancer xenograft tumors. Pancreatology 7:4 (2007), 380–385.
65. [65] Bachem, M.G., et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128:4 (2005), 907–921.
66. [66] Xu, Z., et al. Role of pancreatic stellate cells in pancreatic cancer metastasis. Am. J. Pathol 177:5 (2010), 2585–2596.
67. [67] Muerkoster, S., et al. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res 64:4 (2004), 1331–1337.
68. [68] Akiyama, S.K., Olden, K., Yamada, K.M., Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev 14:3 (1995), 173–189.
69. [69] Bendas, G., Borsig, L., Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int. J. Cell Biol, 2012, 2012, 676731.
70. [70] Bourdoulous, S., et al. Fibronectin matrix regulates activation of RHO and CDC42 GTPases and cell cycle progression. J. Cell Biol 143:1 (1998), 267–276.
71. [71] Mukai, M., et al. Sustained tyrosine-phosphorylation of FAK through Rho-dependent adhesion to fibronectin is essential for cancer cell migration. Anticancer Res 22:6A (2002), 3175–3184.
72. [72] Price, L.S., et al. Activation of Rac and Cdc42 by integrins mediates cell spreading. Mol. Biol. Cell 9:7 (1998), 1863–1871.
73. [73] Ignotz, R.A., Massague, J., Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J. Biol. Chem 261:9 (1986), 4337–4345.
74. [74] Dallas, S.L., et al. Fibronectin regulates latent transforming growth factor-beta (TGF beta) by controlling matrix assembly of latent TGF beta-binding protein-1. J. Biol. Chem 280:19 (2005), 18871–18880.
75. [75] Olmeda, D., et al. Snail silencing effectively suppresses tumour growth and invasiveness. Oncogene 26:13 (2007), 1862–1874.
76. [76] Nawshad, A., et al. TGFbeta3 inhibits E-cadherin gene expression in palate medial-edge epithelial cells through a Smad2-Smad4-LEF1 transcription complex. J. Cell Sci 120:Pt 9 (2007), 1646–1653.
77. [77] Hocevar, B.A., Brown, T.L., Howe, P.H., TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J. 18:5 (1999), 1345–1356.
78. [78] Park, J., Schwarzbauer, J.E., Mammary epithelial cell interactions with fibronectin stimulate epithelial-mesenchymal transition. Oncogene 33:13 (2014), 1649–1657.
79. [79] Dangi-Garimella, S., et al. Epithelial-mesenchymal transition and pancreatic cancer progression. Grippo, P.J., Munshi, H.G., (eds.) Pancreatic Cancer and Tumor Microenvironment, 2012 Trivandrum (India).
80. [80] Jagadeeshan, S., et al. Transcriptional regulation of fibronectin by p21-activated kinase-1 modulates pancreatic tumorigenesis. Oncogene, 2014, 455–464.
81. [81] Yu, M., et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 487:7408 (2012), 510–513.
82. [82] Costa-Silva, B., et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat. Cell Biol, 2015, 816–826.
83. [83] Kahlert, C., Kalluri, R., Exosomes in tumor microenvironment influence cancer progression and metastasis. J. Mol. Med 91:4 (2013), 431–437.
84. [84] Clark, C.E., et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 67:19 (2007), 9518–9527.
85. [85] Schmid-Kotsas, A., et al. Lipopolysaccharide-activated macrophages stimulate the synthesis of collagen type I and C-fibronectin in cultured pancreatic stellate cells. Am. J. Pathol 155:5 (1999), 1749–1758.
86. [86] Folkman, J., Tumor angiogenesis: therapeutic implications. N. Engl. J. Med 285:21 (1971), 1182–1186.
87. [87] Schaffner, F., Ray, A., Dontenwill, M., Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors. Cancers, 2013, 27–47.
88. [88] Bader, B.L., et al. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 95:4 (1998), 507–519.
89. [89] Yang, J.T., Rayburn, H., Hynes, R.O., Embryonic mesodermal defects in alpha 5 integrin-deficient mice. Development 119:4 (1993), 1093–1105.
90. [90] Bhaskar, V., et al. Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits. Invest. New Drugs 26:1 (2008), 7–12.
91. [91] Kuwada, S.K., Drug evaluation: volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody. Curr. Opin. Mol. Ther 9:1 (2007), 92–98.
92. [92] Bhaskar, V., et al. A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J. Transl. Med, 5, 2007, 61.
93. [93] Ricart, A.D., Volociximab, a chimeric monoclonal antibody that specifically binds α5β1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin. Cancer Res 14 (2008), 7924–7929.
94. [94] Yazji, S., Bukowksi, R.M., Kondagunta, V., Figlin, R., Final results from phase II study of volociximab, an a5B1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC). J. Clin. Oncol, 25, 2007, 5094.
95. [95] Cranmer, L.D., Bedikian, A., Ribas, A., Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in metastatic melanoma. J. Clin. Oncol, 24, 2005, Abstr 8011.
96. [96] Valle, J.W., Ramanathan, R.K., Glynne-Jones, R., Anthoney, A., Berlin, J., Yazji, S., Phase II study of volociximab (M200), an A5β1 anti-integrin antibody in metastatic adenocarcinoma of the pancreas. J. Clin. Oncol, 24, 2006, Abstr 4111.
97. [97] Evans, T., Ramanathan, R.K., Yazji, S., Glynne-Jones, R., Anthoney, A., Berlin, J., et al. Final results from cohort 1 of a phase II study of volociximab, an anti-α5β1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC). J. Clin. Oncol, 25, 2007, a4549 Abstract.
98. [98] Besse, B., et al. Phase Ib safety and pharmacokinetic study of volociximab, an anti- 5 1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann. Oncol, 2012, 90–96.
99. [99] Li, G., et al. Dual functional monoclonal antibody PF-04605412 targets integrin 5 1 and elicits potent antibody-dependent cellular cytotoxicity. Cancer Res, 2010, 10243–10254.
100. [100] Becknell, B., Caligiuri, M.A., Natural killer cells in innate immunity and cancer. J. Immunother 31:8 (2008), 685–692.
101. [101] Mateo, J., et al. A first-in-human study of the anti-alpha5beta1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors. Cancer Chemother. Pharmacol 74:5 (2014), 1039–1046.
102. [102] Murphy, P.A., Begum, S., Hynes, R.O., Tumor angiogenesis in the absence of fibronectin or its cognate integrin receptors. PLoS ONE, 2015, e0120872.
103. [103] Hanahan, D., Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315:6015 (1985), 115–122.
104. [104] Wong, P.P., et al. Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. Cancer Cell 27:1 (2015), 123–137.
105. [105] Reynolds, A.R., et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat. Med 15:4 (2009), 392–400.
106. [106] Spivak-Kroizman, T.R., et al. Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. Cancer Res 73:11 (2013), 3235–3247.
107. [107] Aguilera, K.Y., et al. Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma. Cancer Res 74:4 (2014), 1032–1044.
108. [108] Yokoi, K., Fidler, I.J., Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin. Cancer Res 10:7 (2004), 2299–2306.
109. [109] Wong, G.S., Rustgi, A.K., Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis. Br. J. Cancer 108:4 (2013), 755–761.
110. [110] Lomas, A.C., et al. Fibulin-5 binds human smooth-muscle cells through alpha5beta1 and alpha4beta1 integrins, but does not support receptor activation. Biochem. J. 405:3 (2007), 417–428.
111. [111] Eliceiri, B.P., Integrin and growth factor receptor crosstalk. Circ. Res, 2001, 1104–1110.
112. [112] Wang, M., Topalovski1, M., Toombs, J.E., Wright, C.M., Moore, Z.R., Boothman, D.A., et al. Fibulin-5 blocks microenvironmental ROS in pancreatic cancer. Cancer Res 75:23 (2015), 5058–5069.
113. [113] Nakamura, T., et al. DANCE, a novel secreted RGD protein expressed in developing, atherosclerotic, and balloon-injured arteries. J. Biol. Chem 274:32 (1999), 22476–22483.
114. [114] Budatha, M., et al. Extracellular matrix proteases contribute to progression of pelvic organ prolapse in mice and humans. J. Clin. Invest 121:5 (2011), 2048–2059.
115. [115] Midwood, K.S., Orend, G., The role of tenascin-C in tissue injury and tumorigenesis. J. Cell Commun. Signal 3:3–4 (2009), 287–310.
116. [116] Chiquet-Ehrismann, R., et al. Tenascin interferes with fibronectin action. Cell 53:3 (1988), 383–390.
117. [117] Paron, I., et al. Tenascin-C enhances pancreatic cancer cell growth and motility and affects cell adhesion through activation of the integrin pathway. PLoS ONE, 2011, e21684.
118. [118] Huang, W., et al. Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res 61:23 (2001), 8586–8594.
119. [119] Schwarz, R.E., et al. Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation. Cancer Biol. Ther, 2014, 632–639.